It looks like you're using an older version of Internet Explorer which may not display all the features on this site. Upgrade Now » close

Profile: amfAR

Since its creation in 1985, amfAR has been dedicated to ending the global AIDS epidemic through innovative research. amfAR plays a catalytic role in accelerating the pace of HIV/AIDS research and achieving real breakthroughs. Since 1985, amfAR has invested more than $340 million in its mission and has awarded grants to more than 2,000 research teams worldwide.


  • Funded early studies that were critical to the development of protease inhibitors, the powerful drugs that revolutionized the treatment of HIV/AIDS and contributed to a drastic reduction in AIDS-related deaths.
  • Supported research that led to the initial identification and characterization of the compound eventually approved for clinical use as Fuzeon, the first in a new class of AIDS drugs called fusion inhibitors.
  • Pioneered research that ultimately led to the use of antiretroviral drugs to block mother-to-infant HIV transmission. As a result, mother-to-child transmission has been all but eliminated in the industrialized world.
  • Provided early support for the development of microbicides—topical creams or gels that could be discreetly applied prior to sexual intercourse as a means of preventing the sexual transmission of HIV.
  • Created TREAT Asia in 2001. This network of clinics, hospitals, and research institutions is working to ensure the safe and effective delivery of HIV/AIDS treatments throughout Asia and the Pacific.

amfAR profile

Want to learn more?


comments powered by Disqus